Neurodegeneration develops in association with inflammation and demyelination in multiple sclerosis. Available data suggest that the progressive neuroaxonal loss begins in the earliest stages of the disease and underlies the accumulation of clinical disability. The loss of neurons and their processes is driven by a complex molecular mechanism involving cellular and humoral immune histotoxicity, demyelination, reduced neurotrophic support, metabolic impairment, and altered intracellular processes. Here we survey available data concerning the role of autoreactive immunoglobulins in neurotoxicity. A better understanding of molecular pathways leading to immune-mediated neurodegeneration may have key importance in the successful treatment of the disease.
Multiple sclerosis (MS) is an inflammatory demyelinating disorder of the central nervous system (CNS).1 Many studies explored as to how the ignition of autoimmunity occurs, why an immunologically privileged site becomes targeted, what the efferent components of immune attacks are, and how the destruction of myelin and oligodendrocytes leads to the clinical presentation of the disease. A generally accepted view of MS pathogenesis has linked the disease process to myelinspecific, CD4 þ T lymphocytes which, upon activation by unknown factors, migrate through the blood-brain barrier (BBB), engage CNS-related antigenic peptides presented by antigen presenting cells, clonally expand, and exert cytotoxic attacks on oligodendrocytes and myelin. This hypothesis has been largely driven by observations from the experimental autoimmune encephalomyelitis (EAE) model that represents a demyelinating CNS disorder mediated by myelin-specific CD4 þ T cells.
2,3However, recent histological analyses 4 and in vivo studies by magnetic resonance imaging (MRI) and spectroscopy (MRS) 5,6 emphasize that neurodegeneration develops along with inflammatory demyelination. The pathology affects the entire brain, but with different distributions of inflammation, demyelination, and neurodegeneration in the white and gray matter. 7 The neuroaxonal loss is likely to be secondary to inflammation and demyelination, but it begins in the earliest stages of the disease and progresses even after the decline of inflammation. Most importantly, neuroaxonal loss represents the major pathological correlate of clinical disability.
5Further evidence to support the importance of neurodegeneration in MS is obtained from clinical data showing only a partial success of the available disease-modifying drugs (interferons, glatiramer acetate, monoclonal antibodies to antigenic determinants expressed on T lymphocytes), which impede activation and migration of inflammatory cells via the BBB, but have no direct effect on the degenerative processes in CNS. 8 The exploration of neurodegeneration in MS received high priority in the last few years. The data establish that this is a multifactorial process involving loss of myelin protection, immune-mediated histotoxicity, decreased trophic support, mitochondrial damage, metabol...